Published in J Control Release on July 12, 2016
Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients | NCT01845350
Establishment of NF-κB sensing and interleukin-4 secreting mesenchymal stromal cells as an "on-demand" drug delivery system to modulate inflammation. Cytotherapy (2017) 0.75
Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Front Immunol (2017) 0.75
Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice. Mol Ther Methods Clin Dev (2017) 0.75
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
The origin and kinetics of mononuclear phagocytes. J Exp Med (1968) 14.96
Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol (2007) 14.48
Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science (2010) 12.15
Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol (2013) 10.02
Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev (2001) 10.02
Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science (2011) 8.53
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell (2009) 7.62
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol (2012) 7.32
Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 7.26
M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 6.61
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol (2011) 6.34
Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity (2012) 6.18
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature (2005) 5.37
Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation (2003) 5.20
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol (2011) 5.11
The isolation and characterization of murine macrophages. Curr Protoc Immunol (2008) 4.86
Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell (2009) 4.75
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
The cellular and molecular origin of tumor-associated macrophages. Science (2014) 3.89
Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev (2006) 3.71
An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest (2011) 3.69
Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials (2010) 3.54
Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity (2014) 3.54
Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell (2014) 3.52
Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev (2009) 3.43
The macrophage: past, present and future. Eur J Immunol (2007) 3.23
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int (2007) 3.09
Stem cell transplantation: the lung barrier. Transplant Proc (2007) 2.76
Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release (2007) 2.74
Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat Methods (2006) 2.71
Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell (2014) 2.61
Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med (2013) 2.47
Most Tissue-Resident Macrophages Except Microglia Are Derived from Fetal Hematopoietic Stem Cells. Immunity (2015) 2.45
Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev (2007) 2.38
Beyond stem cells: self-renewal of differentiated macrophages. Science (2013) 2.23
Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity (2013) 2.20
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 2.19
Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature (2008) 2.18
Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol (2014) 2.14
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Progressive replacement of embryo-derived cardiac macrophages with age. J Exp Med (2014) 2.10
Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol (2010) 2.05
Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov (2010) 2.04
Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest (2010) 1.96
Induction of the nuclear receptor PPAR-γ by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nat Immunol (2014) 1.95
The effects of osmotic stress on the viscoelastic and physical properties of articular chondrocytes. Biophys J (2002) 1.95
The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science (2014) 1.94
Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. J Control Release (2002) 1.88
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. Blood (2003) 1.79
MafB/c-Maf deficiency enables self-renewal of differentiated functional macrophages. Science (2009) 1.76
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J Biol Chem (2006) 1.70
Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance. J Exp Med (2013) 1.67
Failed renoprotection by alternatively activated bone marrow macrophages is due to a proliferation-dependent phenotype switch in vivo. Kidney Int (2013) 1.66
Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A (2011) 1.66
Two-component protein-engineered physical hydrogels for cell encapsulation. Proc Natl Acad Sci U S A (2009) 1.63
Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood (2009) 1.59
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev (2015) 1.53
Control of the antitumoral activity of human macrophages produced in large amounts in view of adoptive transfer. Eur J Cancer Clin Oncol (1988) 1.52
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol (2012) 1.50
Pulmonary macrophage transplantation therapy. Nature (2014) 1.50
Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res (1982) 1.40
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res (1974) 1.30
Heme-mediated SPI-C induction promotes monocyte differentiation into iron-recycling macrophages. Cell (2014) 1.30
Macrophages: development and tissue specialization. Annu Rev Immunol (2015) 1.30
Activation of murine macrophages. Curr Protoc Immunol (2008) 1.30
The life and fate of mesenchymal stem cells. Front Immunol (2014) 1.27
Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol Aspects Med (2011) 1.27
Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther (2012) 1.27
Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res (1990) 1.23
Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. Adv Drug Deliv Rev (1998) 1.22
Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J Leukoc Biol (2002) 1.19
Generation of mature murine monocytes from heterogeneous bone marrow and description of their properties. J Histochem Cytochem (2011) 1.18
Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release (2015) 1.17
Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant (2009) 1.14
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
Tissue biology perspective on macrophages. Nat Immunol (2015) 1.11
Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol (1998) 1.05
Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation. J Cereb Blood Flow Metab (2013) 1.04
Macrophages as cell-based delivery systems for nanoshells in photothermal therapy. Ann Biomed Eng (2011) 1.03
Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis. Sci Transl Med (2014) 1.03
Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. Elife (2016) 1.03
GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis (2001) 1.03
Genetic and genomic approaches to understanding macrophage identity and function. Arterioscler Thromb Vasc Biol (2015) 1.02
Resident renal mononuclear phagocytes comprise five discrete populations with distinct phenotypes and functions. J Immunol (2013) 1.01
Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res (2011) 1.01
Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia (2011) 1.01
Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression. Sci Transl Med (2014) 1.01
Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. J Immunol (2013) 0.99
STAT6 is required for the anti-inflammatory activity of interleukin-4 in mouse peritoneal macrophages. J Biol Chem (1998) 0.99
Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases. PLoS One (2013) 0.97
Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials (2012) 0.97
Designer lipids for drug delivery: from heads to tails. J Control Release (2014) 0.88
Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. J Control Release (2014) 0.78